Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

palomid 529

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BackgroundLiver kinase B1 (LKB1) loss by gene mutation, loss of heterozygosity, and promoter methylation rarely occurs in… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
2013
2013
BackgroundRecent evidence suggests that neovascular age-related macular degeneration (AMD) may have an immune mediated component… Expand
  • table 1
  • table 2
2013
2013
Palomid 529, a novel dual mTORC1/2 inhibitor has displayed interesting activities in experimental models and is a candidate for… Expand
2012
2012
Keloid disease (KD) is a fibroproliferative lesion of unknown etiopathogenesis that possibly targets the PI3K/Akt/mTOR pathway… Expand
2011
2011
One of the major obstacles in the treatment of hormone-refractory prostate cancer (HRPC) is the development of chemo-resistant… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • table 1
2011
2011
Palomid 529 (8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one), is a novel non-steroidal small… Expand
2010
2010
Palomid 529 (P529) is a small molecule drug created through three generations of computational design. P529 is an anti-tumor… Expand
2009
2009
Radiotherapy (RT) is a common treatment for localised prostate cancer, but can cause important side effects. The therapeutic… Expand
  • table 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
2009
2009
PURPOSE To test the effect of Palomid 529, an inhibitor of the Akt/mTOR pathway, on Müller cell proliferation, subretinal glial… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2008
Highly Cited
2008
It has become clear that the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is central for… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5